

ASX RELEASE

RSNA Update: ~200 New Leads, Four Abstracts, New Features and Products

Wellington, NZ, 7th December 2017: [Volpara Health Technologies](#) (“Volpara”; ASX: VHT), a digital health company focused on early detection of breast cancer by improving quality of screening, is pleased to provide an update following its exhibition at the 103rd Annual Radiological Society of North America (RSNA) meeting, November 26–December 1, 2017.

RSNA is the leading international conference of radiologists, attended by more than 55,000 delegates each year. Held in Chicago, the show attracts screening clinic managers and leaders of the major radiology groups and medical device companies from around the world.

“RSNA was an outstanding success for Volpara. The awareness and interest in Volpara has evolved dramatically, particularly in the past year since we launched VolparaEnterprise™ software and the FDA introduced the EQUIP program, which has placed a greater emphasis on quality control in breast screening,” said Dr Ralph Highnam, CEO of Volpara Health Technologies.

“As a result, the conference statistics show we had some 3,000 people in and around our booth, and generated nearly 200 new leads. These new leads and our sales pipeline present a promising outlook for the rest of the financial year, especially since we have already exceeded last year’s total contract value (TCV) and more than doubled annual recurring revenue (ARR), with the remainder of Q3 and Q4 being our busiest periods,” Dr Highnam added.

Volpara, which had a prominent booth featuring its VolparaEnterprise™ suite, also launched new features for its main platform: VolparaConnect™ software to enable easier, but highly secure, reidentification of women once the data is the cloud; and a new “Risk Counsellor” role license designed to help identify women at high risk due to their breast density alone. Such women, if they prove to be at high risk in a full risk model such as Tyrer-Cuzick 8, then qualify for the recommended and reimbursed breast MRI in many parts of the US.

Two new concepts were also shown to help focus product development for the year ahead: VolparaEnterprise Live!™, a mammography quality control tool that provides the technologist with real-time quality feedback at the gantry; and VolparaEnterprise Now!™, which provides positive public feedback on performance. Both were very positively received and, moving towards productization over the coming year, will be products from which Volpara derives additional recurring revenue.

Volpara’s quantitative analysis tools for breast imaging were also highlighted in four abstracts discussing the importance of quantitative analysis in breast imaging. Leading international institutions Cambridge University and St George’s (UK) used VolparaDensity™ software in their studies, while Italy-based Istituto Oncologico Veneto used VolparaDensity™ software to measure personalised radiation dose.

“RSNA 2017 was simply outstanding. We’re looking forward to RSNA 2018 already,” said Dr Highnam.

ENDS.

About Volpara Health Technologies Limited (ASX: VHT)

Founded in 2009 from research originally conducted at Oxford University, and based in Wellington, New Zealand, VHT facilitates the early detection of breast cancer through its digital health solutions to enable personalised, high-quality breast cancer screening based on automated, objective measurements of breast density.

VHT has numerous patents, trademarks and regulatory clearances, including FDA and CE, supporting its technology and services. An ASX-listed company that raised A\$20M through an IPO and subsequent share placement and rights issue in 2016, VHT has customers and/or research projects in 36 countries.

www.volparasolutions.com

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Buchan
kwilliamson@we-buchan.com
t: +61 3 9866 4722